Which has higher earnings & valuation, ZBIO or VSTM?

Verastem has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zenas BioPharma $10M 161.30 -$377.74M -$8.47 N/A Verastem $30.91M 10.86 -$209.47M -$2.70 N/A

Is ZBIO or VSTM more profitable?

Zenas BioPharma has a net margin of 0.00% compared to Verastem's net margin of -391.17%. Zenas BioPharma's return on equity of -99.99% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Zenas BioPharma N/A -99.99% -58.06% Verastem -391.17% -486.40% -91.56%

Does the media favor ZBIO or VSTM?

In the previous week, Verastem had 18 more articles in the media than Zenas BioPharma. MarketBeat recorded 22 mentions for Verastem and 4 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.75 beat Verastem's score of -0.22 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, MNKD or VSTM?

MannKind has higher revenue and earnings than Verastem. MannKind is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MannKind $348.97M 3.75 $5.86M -$0.07 N/A Verastem $30.91M 10.86 -$209.47M -$2.70 N/A

Is MNKD or VSTM more profitable?

MannKind has a net margin of -6.63% compared to Verastem's net margin of -391.17%. MannKind's return on equity of -11.21% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets MannKind -6.63% -11.21% -3.92% Verastem -391.17% -486.40% -91.56%

Does the media favor MNKD or VSTM?

In the previous week, Verastem had 17 more articles in the media than MannKind. MarketBeat recorded 22 mentions for Verastem and 5 mentions for MannKind. MannKind's average media sentiment score of 0.14 beat Verastem's score of -0.22 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Verastem 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, VSTM or OPK?

Verastem has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 10.86 -$209.47M -$2.70 N/A OPKO Health $606.90M 1.88 -$225.68M -$0.27 N/A

Is VSTM or OPK more profitable?

OPKO Health has a net margin of -36.63% compared to Verastem's net margin of -391.17%. OPKO Health's return on equity of -16.78% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -391.17% -486.40% -91.56% OPKO Health -36.63% -16.78% -10.98%

Does the media refer more to VSTM or OPK?

In the previous week, Verastem had 19 more articles in the media than OPKO Health. MarketBeat recorded 22 mentions for Verastem and 3 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.69 beat Verastem's score of -0.22 indicating that OPKO Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral OPKO Health 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VSTM or LXRX?

In the previous week, Verastem had 19 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 22 mentions for Verastem and 3 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.79 beat Verastem's score of -0.22 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Lexicon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, VSTM or GERN?

Geron has higher revenue and earnings than Verastem. Geron is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 10.86 -$209.47M -$2.70 N/A Geron $183.88M 4.54 -$83.50M -$0.11 N/A

Is VSTM or GERN more profitable?

Geron has a net margin of -35.48% compared to Verastem's net margin of -391.17%. Geron's return on equity of -23.31% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -391.17% -486.40% -91.56% Geron -35.48% -23.31% -10.08%

Does the media refer more to VSTM or GERN?

In the previous week, Verastem had 20 more articles in the media than Geron. MarketBeat recorded 22 mentions for Verastem and 2 mentions for Geron. Geron's average media sentiment score of 1.87 beat Verastem's score of -0.22 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Geron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Verastem (VSTM) Competitors

$3.82 +0.04 (+1.06%)

Closing price 06/29/2026 04:00 PM Eastern

Extended Trading

$3.96 +0.14 (+3.64%)

As of 06/29/2026 07:59 PM Eastern

Compare

VSTM vs. ZBIO, MNKD, OPK, LXRX, and GERN

Should you buy Verastem stock or one of its competitors? MarketBeat compares Verastem with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Verastem include Zenas BioPharma (ZBIO), MannKind (MNKD), OPKO Health (OPK), Lexicon Pharmaceuticals (LXRX), and Geron (GERN). These companies are all part of the "biotechnology" industry.

How does Verastem compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Zenas BioPharma has a beta of -0.71, indicating that its share price is 171% less volatile than the broader market. Comparatively, Verastem has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

88.4% of Verastem shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 1.9% of Verastem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Verastem has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	161.30	-$377.74M	-$8.47	N/A
Verastem	$30.91M	10.86	-$209.47M	-$2.70	N/A

In the previous week, Verastem had 18 more articles in the media than Zenas BioPharma. MarketBeat recorded 22 mentions for Verastem and 4 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.75 beat Verastem's score of -0.22 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Zenas BioPharma currently has a consensus price target of $44.29, suggesting a potential upside of 73.33%. Verastem has a consensus price target of $14.60, suggesting a potential upside of 282.20%. Given Verastem's stronger consensus rating and higher possible upside, analysts clearly believe Verastem is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Zenas BioPharma has a net margin of 0.00% compared to Verastem's net margin of -391.17%. Zenas BioPharma's return on equity of -99.99% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Verastem	-391.17%	-486.40%	-91.56%

Summary

Verastem beats Zenas BioPharma on 11 of the 17 factors compared between the two stocks.

How does Verastem compare to MannKind?

MannKind (NASDAQ:MNKD) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

In the previous week, Verastem had 17 more articles in the media than MannKind. MarketBeat recorded 22 mentions for Verastem and 5 mentions for MannKind. MannKind's average media sentiment score of 0.14 beat Verastem's score of -0.22 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verastem	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

MannKind has a net margin of -6.63% compared to Verastem's net margin of -391.17%. MannKind's return on equity of -11.21% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Verastem	-391.17%	-486.40%	-91.56%

49.6% of MannKind shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 1.9% of Verastem shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

MannKind has higher revenue and earnings than Verastem. MannKind is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.75	$5.86M	-$0.07	N/A
Verastem	$30.91M	10.86	-$209.47M	-$2.70	N/A

MannKind has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Verastem has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

MannKind presently has a consensus target price of $8.97, indicating a potential upside of 111.53%. Verastem has a consensus target price of $14.60, indicating a potential upside of 282.20%. Given Verastem's stronger consensus rating and higher probable upside, analysts plainly believe Verastem is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

MannKind beats Verastem on 9 of the 16 factors compared between the two stocks.

How does Verastem compare to OPKO Health?

Verastem (NASDAQ:VSTM) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

OPKO Health has a net margin of -36.63% compared to Verastem's net margin of -391.17%. OPKO Health's return on equity of -16.78% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
OPKO Health	-36.63%	-16.78%	-10.98%

Verastem has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Verastem has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	10.86	-$209.47M	-$2.70	N/A
OPKO Health	$606.90M	1.88	-$225.68M	-$0.27	N/A

Verastem currently has a consensus price target of $14.60, indicating a potential upside of 282.20%. OPKO Health has a consensus price target of $1.55, indicating a potential upside of 2.65%. Given Verastem's stronger consensus rating and higher possible upside, equities analysts plainly believe Verastem is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

88.4% of Verastem shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 1.9% of Verastem shares are held by company insiders. Comparatively, 44.7% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Verastem had 19 more articles in the media than OPKO Health. MarketBeat recorded 22 mentions for Verastem and 3 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.69 beat Verastem's score of -0.22 indicating that OPKO Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
OPKO Health	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Verastem beats OPKO Health on 9 of the 17 factors compared between the two stocks.

How does Verastem compare to Lexicon Pharmaceuticals?

Verastem (NASDAQ:VSTM) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Lexicon Pharmaceuticals has a net margin of -37.46% compared to Verastem's net margin of -391.17%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Verastem currently has a consensus price target of $14.60, suggesting a potential upside of 282.20%. Lexicon Pharmaceuticals has a consensus price target of $4.55, suggesting a potential upside of 72.35%. Given Verastem's stronger consensus rating and higher possible upside, equities analysts clearly believe Verastem is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Verastem has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

In the previous week, Verastem had 19 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 22 mentions for Verastem and 3 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.79 beat Verastem's score of -0.22 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Lexicon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexicon Pharmaceuticals has higher revenue and earnings than Verastem. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	10.86	-$209.47M	-$2.70	N/A
Lexicon Pharmaceuticals	$49.80M	23.55	-$50.34M	-$0.07	N/A

88.4% of Verastem shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 1.9% of Verastem shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Lexicon Pharmaceuticals beats Verastem on 10 of the 17 factors compared between the two stocks.

How does Verastem compare to Geron?

Verastem (NASDAQ:VSTM) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Geron has a net margin of -35.48% compared to Verastem's net margin of -391.17%. Geron's return on equity of -23.31% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
Geron	-35.48%	-23.31%	-10.08%

Verastem currently has a consensus target price of $14.60, indicating a potential upside of 282.20%. Geron has a consensus target price of $2.50, indicating a potential upside of 92.31%. Given Verastem's stronger consensus rating and higher possible upside, analysts plainly believe Verastem is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

88.4% of Verastem shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 1.9% of Verastem shares are owned by insiders. Comparatively, 1.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Verastem has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Geron has higher revenue and earnings than Verastem. Geron is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	10.86	-$209.47M	-$2.70	N/A
Geron	$183.88M	4.54	-$83.50M	-$0.11	N/A

In the previous week, Verastem had 20 more articles in the media than Geron. MarketBeat recorded 22 mentions for Verastem and 2 mentions for Geron. Geron's average media sentiment score of 1.87 beat Verastem's score of -0.22 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Geron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Verastem beats Geron on 9 of the 17 factors compared between the two stocks.

Get Verastem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VSTM vs. The Competition

Export

Metric	Verastem	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$332.16M	$3.62B	$6.85B	$12.20B
Dividend Yield	N/A	2.21%	2.66%	6.22%
P/E Ratio	-1.41	20.93	26.02	24.36
Price / Sales	10.86	345.52	549.85	102.46
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	5.16	8.71	10.98	6.49
Net Income	-$209.47M	$23.87M	$3.57B	$336.61M
7 Day Performance	-9.26%	3.59%	2.60%	1.25%
1 Month Performance	-11.78%	1.73%	0.93%	0.24%
1 Year Performance	-7.95%	69.03%	36.40%	30.16%

Verastem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VSTM Verastem	2.9848 of 5 stars	$3.82 +1.1%	$14.60 +282.2%	-8.0%	$332.16M	$30.91M	N/A	50
ZBIO Zenas BioPharma	3.619 of 5 stars	$20.80 +5.2%	$44.29 +112.9%	+166.7%	$1.25B	N/A	N/A	N/A	Analyst Upgrade Gap Up
MNKD MannKind	2.872 of 5 stars	$3.89 -1.3%	$8.97 +130.6%	+12.8%	$1.22B	$348.97M	N/A	400	Positive News Analyst Downgrade
OPK OPKO Health	0.9819 of 5 stars	$1.43 +0.7%	$1.55 +8.4%	+14.4%	$1.07B	$581.12M	N/A	1,373
LXRX Lexicon Pharmaceuticals	1.9164 of 5 stars	$2.15 +7.0%	$4.55 +111.6%	+221.6%	$892.84M	$49.80M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VSTM) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verastem (VSTM) Competitors

VSTM vs. ZBIO, MNKD, OPK, LXRX, and GERN

How does Verastem compare to Zenas BioPharma?

Summary

How does Verastem compare to MannKind?

Summary

How does Verastem compare to OPKO Health?

Summary

How does Verastem compare to Lexicon Pharmaceuticals?

Summary

How does Verastem compare to Geron?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM vs. The Competition

Verastem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verastem (VSTM) Competitors

VSTM vs. ZBIO, MNKD, OPK, LXRX, and GERN

How does Verastem compare to Zenas BioPharma?

Which has more risk and volatility, ZBIO or VSTM?

Do institutionals and insiders hold more shares of ZBIO or VSTM?

Which has higher earnings & valuation, ZBIO or VSTM?

Does the media favor ZBIO or VSTM?

Do analysts recommend ZBIO or VSTM?

Is ZBIO or VSTM more profitable?

Summary

How does Verastem compare to MannKind?

Does the media favor MNKD or VSTM?

Is MNKD or VSTM more profitable?

Do institutionals and insiders have more ownership in MNKD or VSTM?

Which has stronger earnings and valuation, MNKD or VSTM?

Which has more risk & volatility, MNKD or VSTM?

Do analysts rate MNKD or VSTM?

Summary

How does Verastem compare to OPKO Health?

Is VSTM or OPK more profitable?

Which has more volatility and risk, VSTM or OPK?

Which has better earnings & valuation, VSTM or OPK?

Do analysts recommend VSTM or OPK?

Do institutionals and insiders have more ownership in VSTM or OPK?

Does the media refer more to VSTM or OPK?

Summary

How does Verastem compare to Lexicon Pharmaceuticals?

Is VSTM or LXRX more profitable?

Do analysts rate VSTM or LXRX?

Which has more volatility and risk, VSTM or LXRX?

Does the media favor VSTM or LXRX?

Which has higher valuation & earnings, VSTM or LXRX?

Do institutionals & insiders hold more shares of VSTM or LXRX?

Summary

How does Verastem compare to Geron?

Is VSTM or GERN more profitable?

Do analysts prefer VSTM or GERN?

Do insiders and institutionals have more ownership in VSTM or GERN?

Which has more volatility and risk, VSTM or GERN?

Which has stronger valuation and earnings, VSTM or GERN?

Does the media refer more to VSTM or GERN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM vs. The Competition

Verastem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools